

RESEARCH

Open Access

The 24-h FEV₁ time profile of olodaterol once daily via Respimat[®] and formoterol twice daily via Aerolizer[®] in patients with GOLD 2–4 COPD: results from two 6-week crossover studies

Gregory J Feldman^{1*}, Jonathan A Bernstein², Alan Hamilton³, Michael C Nivens⁴, Lawrence Korducki⁵ and Craig LaForce⁶

Abstract

These studies evaluated the 24-h forced expiratory volume in 1 sec (FEV₁) profile of once-daily (QD) olodaterol compared to placebo and twice-daily (BID) formoterol in patients with moderate to very severe chronic obstructive pulmonary disease. In two replicate, randomized, double-blind, double-dummy, four-way crossover studies, patients received olodaterol 5 and 10 µg QD, formoterol 12 µg BID, or placebo for 6 weeks in addition to usual-care background maintenance therapy. Co-primary end points were FEV₁ area under the curve from 0–12 h (AUC_{0–12}) response (change from baseline) and FEV₁ AUC from 12–24 h (AUC_{12–24}) response after 6 weeks, with FEV₁ AUC from 0–24 h response identified as a key secondary end point. Other secondary end points included FEV₁ AUC from 0–3 h and trough FEV₁ responses, as well as corresponding forced vital capacity responses. With both olodaterol doses, FEV₁ increased to near-maximal 30 min post-morning dose, which was sustained over 24 h. FEV₁ also increased within 30 min post-morning dose of formoterol and was sustained over 12 h; the second formoterol dose resulted in a further increase, sustained for an additional 12 h. FEV₁ AUC_{0–12} and AUC_{12–24} responses with both QD olodaterol doses and BID formoterol were significantly greater than placebo at 6 weeks ($P < .0001$). Secondary end-point outcomes were consistent with those of the co-primary end points. These data, together with those from the wider phase III clinical program, provide evidence for the 24-h bronchodilator efficacy of olodaterol QD in this patient population.

Trial registry: ClinicalTrials.gov; NCT00931385 and NCT00932646.

Introduction

Long-acting bronchodilators, such as long-acting β_2 -agonists (LABAs) and long-acting muscarinic antagonists, are the cornerstone of pharmacologic therapy for patients with chronic obstructive pulmonary disease (COPD) and are considered central to symptom management (Global Initiative for Chronic Obstructive Lung Disease 2013). The first long-acting bronchodilators available for maintenance treatment of COPD were the LABAs salmeterol and formoterol, which had a <24-h duration of action and so required twice-daily (BID)

dosing (Global Initiative for Chronic Obstructive Lung Disease 2013). The development of newer LABAs, such as indacaterol, with a longer 24-h duration of action (Rodrigo & Neffen 2012) allows for a once-daily (QD) posology (Toy et al. 2011).

Olodaterol is a LABA (Bouyssou et al. 2010a) with high β_2 -receptor selectivity and a near full agonist response at the human β_2 -adrenoceptor (Bouyssou et al. 2010b). Effective 24-h bronchodilation with olodaterol in both asthma and COPD has been confirmed by single-dose studies (van Noord et al. 2011; O'Byrne et al. 2009) and studies over 4 weeks (Joos et al. 2012; O'Byrne et al. 2012; van Noord et al. 2009). The results of these phase II studies provided the rationale to further investigate 5 and 10 µg QD doses of olodaterol in a phase III clinical program.

* Correspondence: gfeld3232@aol.com

¹From S. Carolina Pharmaceutical Research, 141 Harold Fleming Court, North Grove Medical Park, Spartanburg, South Carolina 29303, USA

Full list of author information is available at the end of the article

The comprehensive olodaterol phase III clinical program was designed to evaluate multiple efficacy and safety end points in five sets of paired studies that between them assessed 48-week lung-function efficacy, symptomatic benefit, 24-h bronchodilator profile, and exercise capacity. All studies were conducted in replicate to independently authenticate outcomes (US Department of Health and Human Services et al. 1998).

The primary objective of the replicate studies presented here was to determine the 24-h forced expiratory volume in 1 sec (FEV₁) profile of olodaterol 5 and 10 µg QD in comparison to placebo and formoterol 12 µg BID in patients with moderate to very severe (Global initiative for chronic Obstructive Lung Disease stage 2–4) COPD. Formoterol was chosen as the active comparator because QD LABAs were not available at the time these studies were conducted. These studies are complementary to two replicate pivotal studies that, as a secondary end point, measured FEV₁ responses over 12 h in a subset of patients (NCT00782210 and NCT00782509) (Ferguson et al. 2013) and two replicate 6-week studies (NCT01040689 and NCT01040728) that assessed the 24-h profile of olodaterol QD vs tiotropium (Lange et al. 2013).

In the studies presented here, the study population was chosen to allow evaluation of the 24-h bronchodilation activity of olodaterol in patients closely representative of those in clinical practice, with specific attention given to disease severity, co-morbidities, and background therapies (European Medicines Agency 2012).

Methods

Study design

These were replicate, multicenter, randomized, double-blind, double-dummy, placebo-controlled, four-way crossover studies (registered with ClinicalTrials.gov: NCT00931385 [study 1222.24] and NCT00932646 [study 1222.25]) conducted in the US (Figure 1). Eligible patients

who successfully completed a 2- to 6-week run-in period to ensure clinical stability received each of the following treatments in a random sequence: olodaterol 5 µg QD, olodaterol 10 µg QD, formoterol 12 µg BID, and placebo. Each administration of olodaterol comprised two actuations of the Respimat® inhaler QD, while formoterol was administered via Aerolizer® with each administration comprising one actuation BID. Each treatment period lasted for 6 weeks, with a 14-day washout in between. Patients were evaluated for 14 days following study completion. With the exception of LABAs, patients continued usual-care background COPD maintenance treatment, including short-acting muscarinic antagonists, long-acting muscarinic antagonists, inhaled corticosteroids, and xanthines, throughout the duration of these trials. Patients on LABAs were allowed to switch to short-acting muscarinic antagonists. Salbutamol (100 µg) was provided to all patients as rescue medication.

The study was approved by local ethics committees and carried out according to the Declaration of Helsinki and local regulations. Prior to study initiation, the protocol was approved by the local Institutional Review Board, Independent Ethics Committee, and the Competent Authority. All patients provided written, informed consent prior to the study commencing. Details of the local Institutional Review Boards are provided in Additional file 1: Table S1.

Patients

Patients were enrolled into the study if they met the following inclusion criteria: aged ≥40 years; current or ex-smokers with a smoking history of >10 pack-years; post-bronchodilator FEV₁ <80% of predicted normal; and post-bronchodilator FEV₁/forced vital capacity (FVC) <70%. Key exclusion criteria were: significant disease other than COPD (defined by the investigator as a disease that may put the patient at risk by participating in the study, influence study outcomes, or cause concern




Figure 1 Study design. BID = twice daily; QD = once daily.

with regards to the patient's ability to participate in the study); history of asthma; history of myocardial infarction within 1 year of the screening visit; and unstable or life-threatening cardiac arrhythmia within the past year.

Study outcomes

The primary objective of the study was to determine if olodaterol 5 and 10 µg QD administered via the Respimat®

inhaler provided superior 24-h bronchodilation vs placebo. A secondary objective was to compare the 24-h FEV₁ time profile of QD olodaterol with that of BID formoterol. Co-primary end points were FEV₁ area under the curve from 0 to 12 h (AUC₀₋₁₂) response (defined as change from study baseline) and FEV₁ AUC from 12 to 24 h (AUC₁₂₋₂₄) response after 6 weeks of treatment. FEV₁ AUC from 0 to 24 h (AUC₀₋₂₄) response was




Figure 2 CONSORT diagram illustrating participant flow in (a) study 1222.24 and (b) study 1222.25. AE = adverse event. ^aAll patients who completed 4 treatment periods.

identified as a key secondary end point. Other secondary efficacy variables included FEV₁ measurements at individual time points over 24 h after 6 weeks of treatment, FEV₁ AUC from 0 to 3 h (AUC₀₋₃) response, peak FEV₁ response, and trough FEV₁ response. Corresponding FVC responses after 6 weeks were also measured. Safety end points included adverse events (AEs), vital signs, blood chemistry, and electrocardiogram.

Assessments

All qualifying pulmonary function tests (PFTs) (FEV₁ and FVC) were conducted during the screening visit, and were started at approximately the same time of day for each patient (ie, between 7:00 AM and 9:00 AM; ±30 min maximal difference between the start of the tests on visit 2 and those conducted on subsequent test days). At the start of each treatment period, PFTs were conducted 60 min and 10 min before administration of the morning dose of study drug and at 30 min, 1, 2, and 3 h post-morning dose. Further PFTs were carried out at the end of each treatment period 30 min before administration of the morning dose and at 30 min, 1, 2, 3, 4, 6, 8, 10 h, 11 h 50 min, 12 h 30 min, and 13, 14, 22, 23 h, and 23 h 50 min post-morning dose of study drug (the evening dose of study drug was administered 12 h after the morning dose). Patients were required to stay overnight in the clinic or at a nearby hotel to ensure the quality and timing of PFTs at 22, 23 h, and 23 h 50 min post-dose on the second day of the 24-h PFT visit. All spirometric maneuvers were conducted in triplicate and performed according to American Thoracic Society/European Respiratory Society criteria (Miller et al. 2005). Daily trial medication and rescue medication use were recorded in paper diaries.

Safety end points were assessed in all patients who received at least one dose of study drug. All AEs, irrespective of causality, were monitored and recorded at each visit.

Statistical analysis

A sample size of 80 randomized patients provided 90% power to detect a treatment difference between olodaterol and placebo of 60 mL in FEV₁ AUC₀₋₁₂ and 51 mL in FEV₁ AUC₁₂₋₂₄, based on an estimated standard deviation of 0.160 and 0.140 L, respectively. The conservative randomized discontinuation was estimated to be 20%, resulting in 100 patients randomized.

The primary and secondary efficacy end points were based on the full analysis set, which included all patients with baseline data and evaluable post-dosing data for at least the first co-primary end point. Both primary and secondary end points were analyzed using a mixed-effects repeated measures model with terms for “center”, “patient within center”, “treatment”, and

“period”. Analyses included the fixed categorical effects of “treatment”, “period”, and “random effect for patient”. Compound symmetry covariance structure was used to model within-patient variation. Analyses of AEs, laboratory data, and vital signs were descriptive in nature.

Results

Patient disposition and baseline characteristics

A total of 199 patients were randomized to treatment in both studies (Figure 2): 99 in study 1222.24 and 100 in study 1222.25. All patients were randomized between August 31 and September 15, 2009 (1222.24), and September 01 to 15, 2009 (1222.25) at different US sites involved in each study. All randomized patients received at least one dose of study drug and the majority (86%) completed all four treatment periods. There was a total of 24 occurrences of a patient discontinuing

Table 1 Baseline patient demographics and disease characteristics (treated set)

	Study 1222.24 (n = 99)	Study 1222.25 (n = 100)
Sex, n (%)		
Male	52 (52.5)	54 (54.0)
Female	47 (47.5)	46 (46.0)
Age, mean (SD), years	61.8 (8.9)	63.5 (8.2)
COPD diagnosis, mean (SD), years	7.4 (5.2)	9.4 (7.9)
Pre-bronchodilator		
Mean (SD) FEV ₁ , L	1.241 (0.451)	1.242 (0.504)
Mean (SD) FEV ₁ /FVC, %	49.571 (11.562)	48.673 (12.144)
Mean (SD) % of predicted normal FEV ₁	44.904 (13.908)	46.010 (14.678)
Post-bronchodilator		
Mean (SD) FEV ₁ , L	1.417 (0.494)	1.439 (0.530)
Mean (SD) FEV ₁ change from pre-bronchodilator, L	0.177 (0.158)	0.197 (0.158)
Mean (SD) FEV ₁ /FVC, %	50.224 (11.133)	49.354 (11.460)
Mean (SD) % of predicted normal FEV ₁	51.368 (15.009)	53.242 (14.706)
GOLD stage, n (%)		
2	51 (51.5)	56 (56.0)
3	39 (39.4)	39 (39.0)
4	9 (9.1)	5 (5.0)
BMI, mean (SD), kg/m ²	28.7 (7.7)	27.8 (7.2)
Current smoker, n (%)	60 (60.6)	43 (43.0)
Smoking history, mean (SD), pack-years	54.9 (24.8)	51.2 (26.7)

BMI = body mass index; COPD = chronic obstructive pulmonary disease; FEV₁ = forced expiratory volume in 1 sec; FVC = forced vital capacity; GOLD = Global initiative for chronic Obstructive Lung Disease; SD = standard deviation.

a treatment period (nine in study 1222.24 and 15 in study 1222.25), primarily due to AEs. Patients who discontinued from a treatment period were permitted to remain in the study and continue into the next treatment period. Patient demographics and baseline disease characteristics were well balanced across the studies (Table 1).

Efficacy

The FEV₁ time profiles for both doses of olodaterol were similar over 24 h (Figure 3). Mean FEV₁ increased to near-maximal within 30 min and was sustained over the full 24-h post-dose evaluation period. Following the morning dose of formoterol, mean FEV₁ also increased within 30 min and was comparable to both doses of olodaterol 0 to 3 h post-dose. The FEV₁ time profile of formoterol intersected with the FEV₁ time profile of both olodaterol doses at 4 h and was lower than the FEV₁ responses observed with both doses of olodaterol 4 to 12 h post-dose. The evening dose of formoterol resulted in an additional increase in adjusted mean FEV₁, which was sustained over the 12 to 24-h period (Figure 3).

Primary and key secondary end points

In both studies, both primary end points of FEV₁ AUC₀₋₁₂ and AUC₁₂₋₂₄ responses and the key secondary end point of FEV₁ AUC₀₋₂₄ response were significantly improved with olodaterol 5 µg QD, olodaterol 10 µg QD, and formoterol 12 µg BID compared to placebo ($P < .0001$) (Table 2). Pooled data showed no differences between olodaterol 5 and 10 µg QD compared to formoterol 12 µg BID for the FEV₁ AUC₀₋₁₂ response. However, the adjusted mean FEV₁ AUC₁₂₋₂₄ response for formoterol 12 µg BID was significantly greater than olodaterol 5 and 10 µg QD. For both FEV₁ AUC₀₋₁₂ and AUC₁₂₋₂₄ responses, both doses of olodaterol were similar (Table 3). No statistically significant differences in FEV₁ AUC₀₋₂₄ responses were reported between all three active comparators (Table 3).

Secondary end points

There were statistically significant improvements in the peak FEV₁ response for all active comparators compared to placebo ($P < .0001$) (Table 4). Pooled analysis demonstrated that there were no statistically significant differences in peak FEV₁ responses between the two olodaterol




Figure 3 FEV₁ 24-h profiles of olodaterol 5 and 10 µg and formoterol 12 µg BID compared to placebo at week 6 in (a) study 1222.24 and (b) study 1222.25. BID = twice daily; FEV₁ = forced expiratory volume in 1 sec.

Table 2 Adjusted mean FEV₁ AUC_{0-12h}, AUC_{12-24h} and AUC₀₋₂₄ responses (L) compared to placebo after 6 weeks

FEV ₁ AUC ₀₋₁₂	Treatment		Adjusted ^a mean (95% CI) difference from placebo at 6 weeks		
	n	Adjusted mean (SE)	Mean (SE)	P value	95% CI
Study 1222.24					
Placebo	93	-0.060 (0.020)			
Olodaterol 5 µg QD	92	0.088 (0.021)	0.148 (0.018)	< .0001	0.113, 0.183
Olodaterol 10 µg QD	91	0.088 (0.021)	0.148 (0.018)	< .0001	0.113, 0.183
Formoterol 12 µg BID	90	0.081 (0.021)	0.141 (0.018)	< .0001	0.106, 0.177
Study 1222.25					
Placebo	91	-0.022 (0.024)			
Olodaterol 5 µg QD	92	0.150 (0.024)	0.172 (0.017)	< .0001	0.139, 0.205
Olodaterol 10 µg QD	90	0.152 (0.024)	0.174 (0.017)	< .0001	0.140, 0.208
Formoterol 12 µg BID	90	0.136 (0.024)	0.158 (0.017)	< .0001	0.124, 0.191
FEV ₁ AUC ₁₂₋₂₄					
Study 1222.24					
Placebo	93	-0.123 (0.021)			
Olodaterol 5 µg QD	92	-0.014 (0.022)	0.109 (0.019)	< .0001	0.073, 0.146
Olodaterol 10 µg QD	91	0.004 (0.022)	0.127 (0.019)	< .0001	0.091, 0.164
Formoterol 12 µg BID	90	0.049 (0.022)	0.172 (0.019)	< .0001	0.135, 0.209
Study 1222.25					
Placebo	91	-0.048 (0.025)			
Olodaterol 5 µg QD	92	0.069 (0.025)	0.118 (0.018)	< .0001	0.082, 0.154
Olodaterol 10 µg QD	90	0.072 (0.025)	0.120 (0.018)	< .0001	0.084, 0.157
Formoterol 12 µg BID	90	0.107 (0.025)	0.155 (0.018)	< .0001	0.119, 0.191
FEV ₁ AUC ₀₋₂₄					
Study 1222.24					
Placebo	93	-0.092 (0.020)			
Olodaterol 5 µg QD	92	0.037 (0.021)	0.128 (0.017)	< .0001	0.094, 0.163
Olodaterol 10 µg QD	91	0.046 (0.021)	0.137 (0.017)	< .0001	0.103, 0.172
Formoterol 12 µg BID	90	0.065 (0.021)	0.156 (0.018)	< .0001	0.122, 0.191
Study 1222.25					
Placebo	91	-0.035 (0.024)			
Olodaterol 5 µg QD	92	0.110 (0.024)	0.145 (0.016)	< .0001	0.114, 0.176
Olodaterol 10 µg QD	90	0.112 (0.024)	0.147 (0.016)	< .0001	0.116, 0.179
Formoterol 12 µg BID	90	0.121 (0.024)	0.156 (0.016)	< .0001	0.125, 0.187

AUC₀₋₁₂ = area under the curve from 0 to 12 h; AUC₀₋₂₄ = area under the curve from 0 to 24 h; AUC₁₂₋₂₄ = area under the curve from 12 to 24 h; BID = twice daily; FEV₁ = forced expiratory volume in 1 sec; SE = standard error.

^aBased on a mixed effects repeated measures model. The model includes treatment and period as fixed effects and center and patient within center as random effects, along with compound symmetry as a covariance structure for within-patient variation.

doses; however, peak FEV₁ response for both olodaterol 5 and 10 µg doses was significantly lower than formoterol (-0.036 and -0.034 L, respectively). Additionally, significant improvements in trough FEV₁ and FEV₁ AUC₀₋₃ responses were observed with both doses of olodaterol and formoterol in comparison to placebo (Table 4).

The corresponding FVC responses after 6 weeks' treatment with olodaterol 5 and 10 µg QD and formoterol 12 µg BID were consistent with the FEV₁ AUC responses

and significantly improved vs placebo (Additional file 1: Tables S2-S4). In the pooled analysis, no statistically significant differences between olodaterol doses were observed for FVC AUC₀₋₁₂, FVC AUC₁₂₋₂₄, and FVC AUC₀₋₂₄. Similar to FEV₁ AUC₁₂₋₂₄, the adjusted mean FVC AUC₁₂₋₂₄ response for formoterol 12 µg BID was significantly greater than olodaterol 5 and 10 µg QD (-0.083 L [P = .0001] and -0.074 L [P = .0008], respectively, vs formoterol 12 µg BID). There were no other statistically

Table 3 Adjusted mean FEV₁ AUC₀₋₁₂, FEV₁ AUC₁₂₋₂₄, and FEV₁ AUC₀₋₂₄ responses (L); comparisons across active treatment arms after 6 weeks (pooled analysis)

	Treatment difference					
	FEV ₁ AUC ₀₋₁₂	P value	FEV ₁ AUC ₁₂₋₂₄	P value	FEV ₁ AUC ₀₋₂₄	P value
	Mean (SE)		Mean (SE)		Mean (SE)	
Olodaterol 10 µg QD vs 5 µg QD	0.001 (0.012)	.9527	0.010 (0.013)	.4423	0.005 (0.012)	.6474
Olodaterol 10 µg QD vs formoterol 12 µg BID	0.011 (0.012)	.3588	-0.040 (0.013)	.0024	-0.014 (0.012)	.2268
Olodaterol 5 µg QD vs formoterol 12 µg BID	0.011 (0.012)	.3876	-0.050 (0.013)	.0001	-0.020 (0.012)	.0944

AUC₀₋₁₂ = area under the curve from 0 to 12 h; AUC₀₋₂₄ = area under the curve from 0 to 24 h; AUC₁₂₋₂₄ = area under the curve from 12 to 24 h; BID = twice daily; FEV₁ = forced expiratory volume in 1 sec; QD = once daily; SE = standard error.

significant differences in FVC AUC responses between the active treatment groups. FVC AUC₀₋₁₂, AUC₁₂₋₂₄, AUC₀₋₂₄, and peak and trough FVC responses are shown in Additional file 1: Tables S2–S6, respectively.

Safety

Overall, 129 patients (64.8%) reported at least one AE during the studies. Incidence of AEs across active treatment groups was comparable. A total of 13 patients had AEs that were considered by the investigator to be related to study drug. The most frequently reported treatment-emergent AEs were COPD (17.6%) and upper respiratory tract infection (9.5%) (Table 5). Investigator-defined related AEs for each treatment group are shown in Additional file 1: Table S7. In total, 23 patients across both studies reported at least one serious AE, with the most frequently reported being COPD (three patients, study 1222.24; four patients, study 1222.25). Serious AEs in each treatment group are shown in Additional file 1: Table S7. One death in each study was reported: cardiorespiratory arrest (olodaterol 5 µg, study 1222.24) and respiratory failure (olodaterol 10 µg, study 1222.25). These were not considered by the investigator to be related to study treatment.

No changes indicative of an AE were observed for any laboratory parameters or vital signs with either dose of olodaterol, or formoterol.

Discussion

These replicate studies were designed to complement the evidence of long-term efficacy and safety provided by the pivotal 48-week studies in the olodaterol clinical trial program by evaluating the full 24-h FEV₁ time profile of olodaterol 5 and 10 µg QD in comparison to placebo and formoterol 12 µg BID after chronic dosing.

FEV₁ AUC₀₋₁₂ and AUC₁₂₋₂₄ were chosen as co-primary end points to allow a comparison between the different dosing regimens of olodaterol QD and formoterol BID. FEV₁ AUC₀₋₂₄ was included as a key secondary end point as it offered a comparison of the average 24-h FEV₁ response between the active comparators.

This evaluation demonstrated that FEV₁ AUC₀₋₁₂, AUC₁₂₋₂₄, and AUC₀₋₂₄ responses were all significantly improved with both doses of olodaterol QD and formoterol BID vs placebo. There were distinct differences in the profiles of olodaterol and formoterol over the 24-h dosing interval, as might be expected given the different durations of action and consequent variations in dosing frequency; it should be noted that the methodology used likely overestimates the differences between active treatments. Nevertheless, FEV₁ AUC₀₋₂₄, a reflection of the mean bronchodilator effect over 24 h, was similar for both doses of olodaterol and formoterol. Similar differences in the 24-h FEV₁ time profiles between QD and BID muscarinic antagonists have recently been observed in a trial comparing the 24-h bronchodilatory efficacy of aclidinium BID vs tiotropium QD in patients with moderate to severe COPD (Beier et al. 2013).

While these replicate studies measured lung function over a continuous 24-h dosing interval, there was a necessary pause in testing between 14 and 22 h post-dose to allow patients to have a relatively full night's sleep. As such, it is to be noted that the calculation of FEV₁ AUC₁₂₋₂₄ in the study assumes a linear slope between 14 and 22 h post-dose for both olodaterol and formoterol. The FEV₁ time profiles in Figure 3 clearly show a separation of formoterol and olodaterol as a result of the second peak for formoterol, 1 to 2 h after the evening dose. In contrast, between 22 and 24 h post-dose, the FEV₁ time profiles for olodaterol and formoterol have converged. Due to the necessary pause in lung-function testing between 14 and 22 h post-dose, to allow patients to sleep, the precise time point at which this convergence occurred is not known.

The results for all other secondary outcomes supported those of the primary end points, with FVC responses mirroring FEV₁ outcomes. The inclusion of peak FEV₁ AUC₀₋₃ and trough FEV₁ measurements (at both ends of the daily dosing profile) provided further evidence to confirm the 24-h activity of olodaterol, with the ratio reflecting the degree of bronchodilation that is maintained at the end of the dosing interval in relation to the peak bronchodilation observed in the first hours after

Table 4 Adjusted mean FEV₁ AUC₀₋₃, peak FEV₁, and trough FEV₁ responses (L) compared to placebo after 6 weeks

FEV ₁ AUC ₀₋₃	n	Treatment	Adjusted ^a mean (95% CI) difference from placebo at 6 weeks		
		Adjusted mean (SE)	Mean (SE)	P value	95% CI
Study 1222.24					
Placebo	93	-0.030 (0.020)			
Olodaterol 5 µg QD	92	0.134 (0.021)	0.164 (0.019)	< .0001	0.126, 0.201
Olodaterol 10 µg QD	91	0.135 (0.021)	0.164 (0.019)	< .0001	0.127, 0.202
Formoterol 12 µg BID	90	0.168 (0.021)	0.198 (0.019)	< .0001	0.160, 0.236
Study 1222.25					
Placebo	91	0.004 (0.024)			
Olodaterol 5 µg QD	92	0.190 (0.025)	0.186 (0.019)	< .0001	0.149, 0.223
Olodaterol 10 µg QD	90	0.202 (0.025)	0.198 (0.019)	< .0001	0.162, 0.235
Formoterol 12 µg BID	90	0.217 (0.025)	0.213 (0.019)	< .0001	0.176, 0.250
<i>Peak FEV₁</i>					
Study 1222.24					
Placebo	93	0.034 (0.022)			
Olodaterol 5 µg QD	92	0.208 (0.022)	0.174 (0.020)	< .0001	0.135, 0.214
Olodaterol 10 µg QD	91	0.200 (0.022)	0.166 (0.020)	< .0001	0.127, 0.206
Formoterol 12 µg BID	90	0.251 (0.022)	0.218 (0.020)	< .0001	0.178, 0.257
Study 1222.25					
Placebo	91	0.076 (0.026)			
Olodaterol 5 µg QD	92	0.268 (0.026)	0.192 (0.019)	< .0001	0.154, 0.230
Olodaterol 10 µg QD	90	0.273 (0.026)	0.197 (0.020)	< .0001	0.158, 0.235
Formoterol 12 µg BID	90	0.293 (0.026)	0.217 (0.020)	< .0001	0.178, 0.255
<i>Trough FEV₁</i>					
Study 1222.24					
Placebo	93	-0.093 (0.023)			
Olodaterol 5 µg QD	92	0.012 (0.024)	0.106 (0.021)	< .0001	0.064, 0.147
Olodaterol 10 µg QD	91	0.020 (0.024)	0.113 (0.021)	< .0001	0.072, 0.155
Formoterol 12 µg BID	90	0.040 (0.024)	0.133 (0.021)	< .0001	0.092, 0.175
Study 1222.25					
Placebo	91	0.012 (0.030)			
Olodaterol 5 µg QD	92	0.109 (0.030)	0.097 (0.026)	.0003	0.045, 0.148
Olodaterol 10 µg QD	90	0.115 (0.030)	0.103 (0.026)	.0001	0.051, 0.155
Formoterol 12 µg BID	90	0.093 (0.030)	0.080 (0.026)	.0026	0.028, 0.132

AUC₀₋₃ = area under the curve from 0 to 3 h; BID = twice daily; FEV₁ = forced expiratory volume in 1 sec; QD = once daily; SE = standard error.

^aBased on a mixed effects repeated measures model. The model includes treatment and period as fixed effects and center and patient within center as random effects, along with compound symmetry as a covariance structure for within-patient variation.

dosing. In addition, all FEV₁ and FVC responses observed were in line with those expected for a patient population continuing with standard bronchodilation and corticosteroid maintenance therapy.

The outcomes from these replicate studies support those from earlier phase II trials employing similar end points, which demonstrated that single doses of olodaterol 5 and 10 µg QD provided effective and significant bronchodilation over a 24-h period (Joos et al. 2012;

van Noord et al. 2009). Furthermore, the outcomes from these replicate studies add to the comprehensive set of evidence for the efficacy and safety of olodaterol QD in patients with COPD derived from the wider olodaterol phase III clinical program. A similar 12-h bronchodilation profile for olodaterol was observed in a subset of patients from two independent, 48-week, pivotal studies of olodaterol 5 and 10 µg QD in comparison with placebo (Ferguson et al. 2013). Additionally, outcomes from

Table 5 Frequency of AEs (pooled analysis)

	Pooled analysis				
	Placebo (n = 190)	Olodaterol 5 µg (n = 188)	Olodaterol 10 µg (n = 187)	Formoterol 18 µg (n = 186)	Total (n = 199)
Patients with any AE	60 (31.6)	61 (32.4)	64 (34.2)	49 (26.3)	129 (64.8)
Patients with severe AEs	11 (5.8)	9 (4.8)	6 (3.2)	10 (5.4)	28 (14.1)
Discontinuations due to AEs	4 (2.1)	4 (2.1)	3 (1.6)	3 (1.6)	14 (7.0)
COPD	12 (6.3)	10 (5.3)	9 (4.8)	8 (4.3)	35 (17.6)
Upper respiratory tract infection	4 (2.1)	5 (2.7)	7 (3.7)	7 (3.8)	19 (9.5)
Bronchitis	3 (1.6)	7 (3.7)	4 (2.1)	4 (2.2)	14 (7.0)
Cough	1 (0.5)	6 (3.2)	1 (0.5)	4 (2.2)	12 (6.0)
Headache	2 (1.1)	2 (1.1)	5 (2.7)	2 (1.1)	9 (4.5)
Sinusitis	3 (1.6)	1 (0.5)	3 (1.6)	3 (1.6)	9 (4.5)
Urinary tract infection	4 (2.1)	0	4 (2.1)	2 (1.1)	9 (4.5)
Diarrhea	1 (0.5)	0	2 (1.1)	2 (1.1)	5 (2.5)
Nausea	3 (1.6)	1 (0.5)	0	1 (0.5)	5 (2.5)
Muscle spasms	1 (0.5)	1 (0.5)	1 (0.5)	2 (1.1)	5 (2.5)
Chest pain	2 (1.1)	1 (0.5)	2 (1.1)	0	5 (2.5)
Pneumonia	1 (0.5)	0	2 (1.1)	1 (0.5)	4 (2.0)
Respiratory tract congestion	3 (1.6)	0	1 (0.5)	0	4 (2.0)

AE = adverse event; COPD = chronic obstructive pulmonary disease.

similar phase III, replicate, 6-week studies demonstrated that olodaterol 5 and 10 µg QD significantly improved FEV₁ AUC₀₋₁₂ and AUC₁₂₋₂₄ responses compared to placebo, with a 24-h bronchodilator profile comparable to tiotropium (Lange et al. 2013).

A question that arises from the difference in the 24-h lung-function profiles of olodaterol QD and formoterol BID is whether the second evening peak in FEV₁ with formoterol is associated with any improvements in night-time symptoms compared to olodaterol. This cannot be determined from our studies as no assessment of daytime and night-time symptoms was performed. However, two long-term, 48-week studies within the olodaterol phase III program were conducted using the BID comparator formoterol (Koch et al. 2013). Despite the second dose of formoterol being given in the evening, there were no differences between active treatments in night-time rescue medication usage at any time point in these studies (Boehringer Ingelheim, data on file). These data suggest that the evening peak in lung function with formoterol was not manifested in terms of advantages in night-time symptomatology.

Treatment with both doses of olodaterol and formoterol was well tolerated and incidence of AEs across treatment groups was comparable with the most commonly reported AEs: COPD and upper respiratory tract infection. In addition, safety outcomes in these studies were consistent with those reported in the pivotal studies.

Conclusions

These data, together with those from the wider phase III clinical program, provide evidence for the 24-h bronchodilator efficacy of olodaterol QD in patients with moderate to very severe COPD, with no differences in efficacy and tolerability observed between olodaterol 5 and 10 µg QD. Results from this study support the selection of the 5 µg dose for later use in clinical practice.

Additional file

Additional file 1: Supplementary tables S1 to S7.

Abbreviations

AE: Adverse event; AUC₀₋₃: Area under the curve from 0 to 3 h; AUC₀₋₁₂: Area under the curve from 0 to 12 h; AUC₀₋₂₄: Area under the curve from 0 to 24 h; AUC₁₂₋₂₄: Area under the curve from 12 to 24 h; BID: Twice daily; COPD: Chronic obstructive pulmonary disease; FEV₁: Forced expiratory volume in 1 sec; FVC: Forced vital capacity; LABA: Long-acting β₂-agonist; QD: Once daily; PFT: Pulmonary function test.

Competing interests

Dr Feldman: Principal Investigator for Boehringer Ingelheim. Dr Bernstein: Principal Investigator for Boehringer Ingelheim with funding provided to research center. Dr Hamilton, Dr Nivens and Mr Korducki: employees of Boehringer Ingelheim. Dr LaForce: no competing interest.

Authors' contributions

Dr GJF: contributed to the study conception and design, provided oversight of the studies and analysis of the data, and was responsible for the drafting, review, and final approval of the manuscript. Dr JAB: served as Principal Investigator, participated in discussions regarding protocol design at

investigator's meeting, read and edited the manuscript. Dr AH: contributed to writing and implementing the protocol, overseeing the Principal Investigators, writing the clinical trial report, and approving the final manuscript. Dr MCN: contributed to writing and implementing the protocol, overseeing the Principal Investigators, writing the clinical trial report, and approving the final manuscript. Mr LK: contributed to the study conception and design, provided oversight of the studies and analysis of the data, and was responsible for the drafting, review, and final approval of the manuscript. Dr CLF: contributed to writing and implementing the protocol, overseeing the Principal Investigators, writing the clinical trial report, and approving the final manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. They take full responsibility for the scope, direction, content of, and editorial decisions relating to, the manuscript, were involved at all stages of development, and have approved the submitted manuscript. The authors received no compensation related to the development of the manuscript. This work was supported by Boehringer Ingelheim Pharma GmbH & Co. KG. Medical writing assistance was provided by Tanya Chaudry, PhD, of Complete HealthVizion, which was contracted and compensated by Boehringer Ingelheim Pharma GmbH & Co. KG.

Financial/Nonfinancial disclosures

The authors have reported the following conflicts of interest: Dr Feldman and Dr Bernstein have been Principal Investigators for pharmaceutical company studies. Dr Hamilton, Dr Nivens, and Mr Korducki are employees of Boehringer Ingelheim. Dr LaForce has no conflicts of interest.

Funding/Support

This work was supported by Boehringer Ingelheim Pharma GmbH & Co. KG.

Notation of prior abstract publication

European Respiratory Society Annual Congress, Barcelona, Spain, September 7–11, 2013.

Role of sponsors

These studies were funded by Boehringer Ingelheim. All data were interpreted by the authors.

Author details

¹From S. Carolina Pharmaceutical Research, 141 Harold Fleming Court, North Grove Medical Park, Spartanburg, South Carolina 29303, USA. ²Department of Internal Medicine, Bernstein Clinical Research Center, Cincinnati, Ohio, USA. ³Boehringer Ingelheim, Burlington, Ontario, Canada. ⁴Boehringer Ingelheim Pharmaceuticals Inc., Biberach an der Riss, Germany. ⁵Boehringer Ingelheim Pharma GmbH & Co. KG, Ridgefield, Connecticut, USA. ⁶North Carolina Clinical Research, Raleigh, North Carolina, USA.

Received: 11 February 2014 Accepted: 22 July 2014

Published: 9 August 2014

References

- Beier J, Kirsten A-M, Mróz R, Segarra R, Chuecos F, Caracta C, Garcia Gil E (2013) Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. *COPD* 10:511–522
- Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, Schnapp A (2010a) Pharmacological characterization of olodaterol, a novel inhaled β_2 -adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. *J Pharmacol Exp Ther* 334:53–62
- Bouyssou T, Hoenke C, Rudolf K, Lustenberger P, Pestel S, Sieger P, Lotz R, Heine C, Büttner FH, Schnapp A, Konetzki I (2010b) Discovery of olodaterol, a novel inhaled β_2 -adrenoceptor agonist with a 24 h bronchodilatory efficacy. *Bioorg Med Chem Lett* 20:1410–1414
- European Medicines Agency (2012) Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf. Last updated 2012. Accessed 7 Aug 2013

- Ferguson G, Feldman G, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P (2013) Lung function efficacy of olodaterol QD delivered via Respimat in COPD patients: Results from two 48-week studies [abstract]. *Eur Respir J* 42 (Suppl 57):5s, abstract 187
- Global Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Last updated 2013. Accessed 5 Mar 2014
- Joos G, Aumann JL, Coeck C, Korducki L, Hamilton AL, van Noord J (2012) Comparison of 24-hour FEV₁ profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β_2 -agonist, in patients with COPD [abstract]. *Am J Respir Crit Care Med* 185:abstract A2930
- Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P (2013) Lung function efficacy of olodaterol QD delivered via Respimat versus placebo and formoterol BID in patients with COPD: two 48-week studies. Poster P764 presented at the European Respiratory Society Annual Congress, Barcelona, Spain
- Lange P, Aumann J-L, Derom E, Hamilton A, Tetzlaff K, Ting N, van Noord JA (2013) The 24-h FEV₁ time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies [abstract]. *Eur Respir J* 42(Suppl 57):982s, abstract 4635
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wang J (2005) Standardisation of spirometry. *Eur Respir J* 26:319–338
- O'Byrne PM, van der Linde J, Cockcroft DW, Gauvreau GM, Brannan JD, FitzGerald M, Watson RM, Milot J, Davis B, O'Connor M, Hart L, Korducki L, Hamilton AL, Boulet L-P (2009) Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β_2 -agonist, in patients with mild asthma. *J Allergy Clin Immunol* 124:1217–1221
- O'Byrne PM, D'Urzo T, Gahlemann M, Hart L, Wang F, Beck E (2012) Dose-finding study of once-daily treatment with olodaterol, a novel long-acting β_2 -agonist, in patients with asthma [abstract]. *Am J Respir Crit Care Med* 185:abstract A3963
- Rodrigo GJ, Neffen H (2012) Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review. *Chest* 142:1104–1110
- Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS (2011) Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. *Respir Med* 105:435–441
- US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (1998) Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf>. Last updated 1998. Accessed 24 Jul 2013
- van Noord JA, Korducki L, Hamilton A, Koker P (2009) Four weeks once daily treatment with BI 1744 CL, a novel long-acting β_2 -agonist, is effective in COPD patients [abstract]. *Am J Respir Crit Care Med* 179:abstract A6183
- van Noord JA, Smeets JJ, Drenth BM, Rascher J, Pivovarova A, Hamilton AL, Cornelissen PJG (2011) 24-hour bronchodilation following a single dose of the novel β_2 -agonist olodaterol in COPD. *Pulm Pharmacol Ther* 24:666–672

doi:10.1186/2193-1801-3-419

Cite this article as: Feldman *et al.*: The 24-h FEV₁ time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies. *SpringerPlus* 2014 **3**:419.